Preeclampsia Market Size & Growth Forecast 2027–2036, By Segments (Test Type, End Use, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Jump to Content
Market Size and Growth Outlook
Preeclampsia Market size was over USD 1.45 billion in 2026 and is likely to grow at a 9.67% CAGR between 2027 and 2036, exceeding USD 3.65 billion by 2036. The industry revenue for 2027 is assessed at USD 1.57 billion.
Get more details on this report
Request Free Sample ReportPreeclampsia Market Intelligence Snapshot
Regional Market Dynamics
- North America accounted for 43.1% of the market, supported by advanced maternal healthcare infrastructure, established prenatal screening, specialized obstetric care, and increasing adoption of biomarker-based diagnostics for high-risk pregnancies.
- Asia Pacific is growing fastest as maternal health awareness increases, prenatal services expand, and investments improve hospital infrastructure, diagnostic accessibility, and early identification of high-risk pregnancies.
Segment Momentum
- Blood tests accounted for 60.74% of the market in 2026, supported by their role in assessing platelet levels, liver and kidney function, disease severity, and potential pregnancy complications.
- Diagnostic centers held a 38.07% share in 2026 and are projected to grow fastest, supported by specialized testing capabilities, increasing prenatal screening awareness, and referrals from healthcare professionals.
Market Expansion Drivers
- Rising prevalence of hypertension and preeclampsia awareness.
- Development of novel therapeutics for preeclampsia.
- Government healthcare funding and maternal health programs.
Leading Market Participants
- Key companies in the preeclampsia market include Bayer (Germany), Pfizer (USA), Novartis (Switzerland), GlaxoSmithKline (UK), AstraZeneca (UK), Roche (Switzerland), Johnson & Johnson (USA), Merck & Co. (USA), Takeda (Japan), Sanofi (France).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 1.45 billion
- 2027 Estimated Market Size: USD 1.57 billion
- Projected Market Size: USD 3.65 billion by 2036
- Growth Forecast: 9.67% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Test Type (Blood Tests) | End Use (Diagnostic Centers) | Application (Universal Screening)
- Emerging Opportunity Segment: Test Type (Blood Tests) | End Use (Diagnostic Centers) | Application (Universal Screening)
Market Growth Drivers and Industry Trends
Growth Drivers
The rising prevalence of hypertension during pregnancy, combined with increasing awareness of preeclampsia and its potential maternal and fetal complications, is driving greater demand for early diagnosis, monitoring, and treatment. Healthcare providers are placing greater emphasis on identifying high-risk pregnancies and managing blood pressure-related complications, supporting the adoption of diagnostic and therapeutic approaches that can improve maternal care and pregnancy outcomes.
Growth Drivers
The development of novel therapeutics for preeclampsia is expanding treatment opportunities for patients with limited existing options and encouraging greater investment in targeted approaches to disease management. Advances in understanding the underlying biological mechanisms of preeclampsia are supporting the exploration of therapies designed to address disease progression, manage associated complications, and improve clinical outcomes during pregnancy.
Growth Drivers
Government healthcare funding and maternal health programs are supporting greater access to prenatal screening, pregnancy monitoring, and specialized maternal care services. Increased emphasis on reducing pregnancy-related complications is encouraging healthcare systems to strengthen early detection and management of preeclampsia, while public health initiatives are improving awareness and access to appropriate care for women at elevated risk.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising prevalence of hypertension and preeclampsia awareness | 3% | Short term (≤ 2 yrs) | North America; Europe; Spillover: Asia Pacific | Medium | Fast |
| Development of novel therapeutics for preeclampsia | 4% | Medium term (2–5 yrs) | North America; Europe | Low | Moderate |
| Government healthcare funding and maternal health programs | 2.5% | Long term (5+ yrs) | Europe; North America | High | Moderate |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
North America (Largest Region)
The North America preeclampsia market accounted for the largest regional share of 43.1%, driven by advanced maternal healthcare infrastructure, increasing awareness of pregnancy-related complications, and growing emphasis on early diagnosis and risk assessment. The region benefits from established prenatal screening practices, access to specialized obstetric care, and the widespread availability of diagnostic services for monitoring high-risk pregnancies. Increasing recognition of the serious maternal and fetal complications associated with preeclampsia is encouraging healthcare providers to prioritize early identification, regular blood pressure monitoring, and timely clinical intervention. Advancements in biomarker-based testing and maternal health diagnostics are also supporting improvements in risk stratification and clinical decision-making. In addition, continued research into the underlying mechanisms of preeclampsia and the development of improved diagnostic approaches are strengthening the region's clinical capabilities.
Asia Pacific (Fastest-Growing Region)
The Asia Pacific preeclampsia market is expected to grow at the fastest pace, driven by increasing awareness of maternal health, expanding access to prenatal healthcare, and growing efforts to improve pregnancy outcomes. The region's large maternal population and varying levels of access to specialized obstetric services are creating demand for accessible screening, early diagnosis, and effective pregnancy monitoring solutions. Governments and healthcare organizations are placing greater emphasis on maternal healthcare programs, strengthening prenatal services, and improving the identification of high-risk pregnancies. The expansion of hospital infrastructure and diagnostic capabilities is also supporting the adoption of blood pressure monitoring, laboratory testing, and emerging biomarker-based diagnostic approaches. Furthermore, increasing healthcare expenditure and broader awareness of pregnancy-related hypertensive disorders are encouraging expectant mothers to seek regular antenatal assessments. Continued improvements in maternal healthcare delivery, diagnostic accessibility, and clinical awareness are expected to support the region's growth in the preeclampsia market.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation HubiScaleNascentDeveloping Advanced | |||||
| Cost-Sensitive RegioniScaleLowMedium High | |||||
| Regulatory EnvironmentiScaleRestrictiveNeutral Supportive | |||||
| Demand DriversiScaleWeakModerate Strong | |||||
| Development StageiScaleEmergingDeveloping Developed | |||||
| Adoption RateiScaleLowMedium High | |||||
| New Entrants / StartupsiScaleSparseModerate Dense | |||||
| Macro IndicatorsiScaleWeakStable Strong |
Key Country Insights
United States 🇺🇸
Advanced Maternal CareThe U.S. prioritizes earlier identification and management of preeclampsia through improved screening, maternal monitoring, and novel therapeutics. Clinical adoption is supported by established obstetric care pathways and ongoing emphasis on reducing severe maternal complications through timely intervention.
Germany 🇩🇪
Structured Prenatal ManagementGermany emphasizes systematic prenatal screening and evidence-based management of preeclampsia within established maternal healthcare pathways. Priorities include strengthening early risk assessment, specialist monitoring, and access to interventions that can reduce complications for mothers and newborns.
Japan 🇯🇵
Maternal Risk MonitoringJapan focuses on careful antenatal surveillance and early management of hypertensive pregnancy disorders, supported by structured obstetric care. Market priorities include reliable maternal and fetal monitoring, risk stratification, and clinical approaches that improve management of preeclampsia while limiting adverse pregnancy outcomes.
South Korea 🇰🇷
Digital Maternal MonitoringSouth Korea is positioned around technology-enabled maternal monitoring, with opportunities for more integrated detection and management of pregnancy-related hypertension. Clinical priorities include improving risk identification, strengthening prenatal surveillance, and incorporating diagnostic or monitoring technologies into specialist obstetric care.
France 🇫🇷
Integrated Obstetric CareFrance emphasizes coordinated prenatal screening and specialist management of preeclampsia within its structured maternal healthcare system. Priorities center on early recognition of high-risk pregnancies, consistent monitoring, and interventions that support maternal safety while reducing complications associated with severe disease.
Italy 🇮🇹
Risk-Based Pregnancy CareItaly's preeclampsia market is shaped by risk-based prenatal assessment and specialist obstetric management. Key priorities include identifying susceptible pregnancies earlier, maintaining close maternal and fetal surveillance, and improving access to evidence-based interventions across hospital and maternal care settings.
Preeclampsia Market Share (%), by Test Type, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportTest Type Segment Analysis: Blood Tests (Largest & Fastest-Growing Segment)
The blood tests segment accounted for the largest share of 60.74% in the preeclampsia market in 2026, while also representing the fastest-growing test type. Its leading position is supported by the important role of blood-based assessments in identifying physiological changes associated with preeclampsia and supporting timely clinical evaluation. Blood tests can provide valuable information on indicators such as platelet levels, liver function, and kidney function, helping healthcare professionals assess disease severity and identify potential complications. Their integration into routine maternal health evaluations also supports broader adoption, particularly when patients present with symptoms or clinical findings that may indicate hypertensive disorders during pregnancy. Continued emphasis on early diagnosis, maternal monitoring, and risk assessment is expected to sustain demand for blood-based testing as healthcare providers seek reliable diagnostic information to guide treatment and pregnancy management decisions.
End Use Segment Analysis: Diagnostic Centers (Largest & Fastest-Growing Segment)
The diagnostic centers segment accounted for the largest share of 38.07% in the preeclampsia market in 2026 and is also the fastest-growing end-use segment. Diagnostic centers play an important role in expanding access to specialized testing and facilitating timely evaluation of pregnant women suspected of having preeclampsia. Their availability of laboratory infrastructure and diagnostic capabilities enables healthcare providers to obtain blood-based and other relevant test results that support disease identification and ongoing assessment. Growing awareness of the importance of prenatal screening and early detection is encouraging expectant mothers to undergo appropriate diagnostic evaluations, while increasing referrals from obstetricians and other healthcare professionals are further supporting utilization. In addition, the ability of diagnostic centers to provide dedicated testing services and efficient result processing is contributing to their growing relevance in maternal healthcare, particularly as healthcare systems place greater emphasis on preventing severe complications through earlier clinical intervention.
Application Segment Analysis: Universal Screening (Largest & Fastest-Growing Segment)
The universal screening segment accounted for the largest share of the preeclampsia market and is also the fastest-growing application. Its strong position is driven by increasing emphasis on identifying women at risk of preeclampsia before serious complications develop. Universal screening supports systematic assessment during pregnancy, allowing healthcare professionals to monitor relevant clinical indicators and recognize potential risk factors at an earlier stage. The growing focus on preventive maternal healthcare is encouraging broader adoption of screening approaches that can be incorporated into routine antenatal care rather than relying solely on symptom-based evaluation. In addition, greater awareness among healthcare providers and expectant mothers regarding the potentially serious consequences of undetected preeclampsia is strengthening demand for comprehensive screening practices. As healthcare systems continue to prioritize early detection, risk stratification, and proactive pregnancy management, universal screening is expected to remain an important application in the preeclampsia diagnostic landscape.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Test Type | Blood Tests, Urinalysis | Blood Tests | Blood Tests |
| End Use | Hospitals, Specialty Clinics, Diagnostic Centers, Others | Diagnostic Centers | Diagnostic Centers |
| Application | Universal Screening, Targeted Testing, Monitoring & Recurrence Surveillance | Universal Screening | Universal Screening |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Analyst Perspective:
Competitive dynamics in the preeclampsia market are increasingly centered on delivering holistic, risk-stratified care solutions that span early prediction, targeted intervention, and continuous management. Early-onset biomarker assays offer significant strategic differentiation, yet their market value depends on validating sensitivity across diverse gestational ages and seamless integration into clinical risk protocols. Concurrently, biopharmaceutical developers targeting anti-angiogenic pathways face high clinical hurdles, where success hinges on demonstrating disease-modifying efficacy while maintaining strict maternal-fetal safety profiles. As digital health technologies expand, remote patient monitoring tools gain commercial traction by enabling outpatient surveillance; however, long-term vendor differentiation ultimately relies on aligning these monitoring insights with established clinical guidelines, robust escalation workflows, and authorized regulatory frameworks.
Key companies in the preeclampsia market:
- Bayer (Germany)
- Pfizer (USA)
- Novartis (Switzerland)
- GlaxoSmithKline (UK)
- AstraZeneca (UK)
- Roche (Switzerland)
- Johnson & Johnson (USA)
- Merck & Co. (USA)
- Takeda (Japan)
- Sanofi (France)
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Bayer (Germany) | |||||||
| Pfizer (USA) | |||||||
| Novartis (Switzerland) | |||||||
| GlaxoSmithKline (UK) | |||||||
| AstraZeneca (UK) | |||||||
| Roche (Switzerland) | |||||||
| Johnson & Johnson (USA) | |||||||
| Merck & Co. (USA) | |||||||
| Takeda (Japan) | |||||||
| Sanofi (France) |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Revvity | August 2026 | Revvity launched the CE-IVDR certified SuperFlex prenatal screening system tailored for small and mid-sized laboratories, incorporating preeclampsia testing capabilities into its diagnostic portfolio. The system is engineered to broaden access to prenatal screening and support clinical adoption of preeclampsia risk assessment in scalable testing environments. |
| Trinity Biotech | August 2025 | Trinity Biotech commercially launched an FDA-cleared preeclampsia testing service, utilizing the PreClara Ratio sFlt-1/PlGF test in collaboration with Thermo Fisher. Offered as a reference-lab service to support risk stratification and clinical decision-making in the U.S., the service leverages Trinity's Immco reference laboratory and commercial infrastructure. |
| Roche | February 2025 | Roche received FDA 510(k) clearance for its Elecsys sFlt-1/PlGF ratio prognostic test. The diagnostic is designed to stratify hospitalized pregnant women with hypertensive disorders into low- and high-risk categories for developing severe preeclampsia within two weeks, serving as an objective adjunct to standard clinical assessments. |
| Gravidas Diagnostics Inc. | December 2024 | Gravidas Diagnostics Inc., supported by Cedars-Sinai Technology Ventures, secured a $3 million federal grant from the Advanced Research Projects Agency for Health. The funding aims to develop an affordable, home-based fingerstick test for the early detection of preeclampsia, targeting earlier clinical identification through an accessible diagnostic approach. |
| Trinity Biotech | September 2024 | Trinity Biotech acquired Metabolomics Diagnostics, developer of the PrePsia early-pregnancy predictive test, for a modest enterprise value. The acquisition integrated mass-spectrometry and machine-learning capabilities to commercialize the first-trimester preeclampsia risk prediction test through Trinity's Immco reference laboratory in the U.S. and pursue international rollout, with initial revenues projected for 2025. |
| DiaMedica Therapeutics | June 2024 | DiaMedica Therapeutics expanded its DM199 (rinvecalinase alfa) clinical development program into preeclampsia. The protein therapeutic is intended to improve blood vessel function, representing an evaluation of the treatment in a severe pregnancy-related condition associated with elevated blood pressure and associated maternal and fetal risks. |
| Labcorp | May 2024 | Labcorp launched a first-trimester blood test designed to evaluate preeclampsia risk between 11 and 14 weeks of gestation. The diagnostic generates a risk score for developing preeclampsia before 34 weeks, expanding laboratory screening capabilities and enabling earlier identification of patients at elevated risk. |
| Labcorp | January 2024 | Labcorp introduced the BRAHMS sFlt-1/PlGF KRYPTOR Test System as the first FDA-cleared blood test assessing the risk of progression to severe preeclampsia. The system measures the ratio of angiogenic biomarkers sFlt-1 and PlGF to help clinicians identify high-risk patients within two weeks, addressing the limitations of traditional diagnostic methods. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Preeclampsia Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Disease Severity | Mild Preeclampsia, Severe Preeclampsia, Eclampsia |
| Patient Risk Profile | Low-Risk Pregnancy, Moderate-Risk Pregnancy, High-Risk Pregnancy |
| Treatment Approach | Antihypertensive Therapy, Magnesium Sulfate Therapy, Corticosteroid Therapy, Delivery & Obstetric Management |
Preeclampsia Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Maternal Care Pathway Optimization |
|
| Early Detection & Screening Strategies |
|
| Postpartum Risk Management Strategies |
|
Need a different cut of the data?
Request Custom ResearchFrequently Asked Questions
What is the market size of the preeclampsia market?
How much is the preeclampsia industry expected to grow by 2036?
How is the focus on early detection influencing the preeclampsia market?
How are novel therapeutics changing investment priorities in preeclampsia management?
Which test type segment holds the largest share of the preeclampsia market?
Which end-use segment is expected to grow fastest?
Why does North America hold the largest share of the preeclampsia market?
What is driving the fastest growth in Asia Pacific's preeclampsia market?
Who are the major participants shaping the preeclampsia landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.
Delivery
Published
Available
Support
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook